[The regulatory action of dipeptide "Deglutam" on the glutamine metabolized enzymes in the carcinosarcoma SM-1 cells].
The influence of modified antineoplaston AS2-1 (with altered ratio of L-phenylalanine and L-glutamine derivatives, "Deglutam") on the activity of glutamine synthetase, glutaminase isoforms in the carcinosarcoma SM-1, tumor weight, per cent of the inhibition of tumor growth and blood impact index was investigated in rats with carcinosarcoma SM-1. The preparation was administered in the dose of 125 mg/kg twice a day for 12 days (on the 7th day after tumor transplantation). Intensive growth of carcinosarcoma SM-1 was accompanied by activtion of the glutamine metabolizing enzymes. The dose-response effect of "Deglutam" on the studied enzymes depended on the mode of preparation administration. The intragastric administration of the preparation caused the same effect on the glutamine metabolizing of SM-1 cells; as it was earlier observed in rat liver. Administration of the modified preparation ANP AS2-1 (containing L-glutamine derivatives) influences regulation of glutamine metabolism in carcinosarcoma SM-1 cells, possibly, due to formation of substrates in the tissues of the tumor-bearing body similar to glutamine. It is also possible that in the tumor tissues these enzymes have different affinity to glutamine. This may explain greater effectiveness of the synthetic preparation on the basis of L-glutamine derivatives rather than the amino acid itself.
D000818:Animals; D002296:Carcinosarcoma / Q000188:drug therapy / Q000378:metabolism*; D004151:Dipeptides / Q000008:administration & dosage*; D004338:Drug Combinations; D005973:Glutamine / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000378:metabolism*; D008297:Male; D010648:Phenylacetates / Q000008:administration & dosage*; D051381:Rats; D017208:Rats, Wistar
D004151:Dipeptides; D004338:Drug Combinations; D010648:Phenylacetates; D005973:Glutamine; C092038:antineoplaston AS 2-1